« Return to News | Awards & Advancement

SIRO Clinpharm named Indian CRO of the Year 2012

Monday, October 1, 2012 09:20 AM

SIRO Clinpharm, a drug development solutions provider, has been awarded the 'Indian CRO of the Year 2012' by Frost & Sullivan, a global growth partnership and consulting firm.

The award was received by Gopakumar Menon, CEO, SIRO Clinpharm on behalf of the employees. "I am proud to receive this award as an ambassador of exceptional professionals across three continents, whose daily pursuit of excellence has resulted in SIRO Clinpharm receiving this award for two consecutive years," he said.

Ajaykumar Sharma, associate director of pharma and biotech, South Asia and Middle East, Frost & Sullivan, added, "With all the regulatory challenges which had taken off the sheen from the Indian CRO industry in the last few years, it is amazing to see a company repeating this feat for the second year in a row.”

The award is a testimony to SIRO Clinpharm's commitment in supporting its stakeholders through ethical, transparent and best-in-class services.

"As the Indian markets open to the western world, there are a number of challenges we face not just as a company but as an industry,” said Vatsal Shah, head of medical writing and pharmacovigilance, SIRO. “However, we have been able to convert these challenges into opportunities by ensuring process excellence, improving service delivery and focusing on training and development of our resources—thus, delivering a spectrum of services that is unique to the industry.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.